Clinical Trial Update: Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State [Phase 1]

View source ↗

Summary

Phase 1 trial update assessing intra-subject variability after administration of activated recombinant human Factor VII (eptacog alfa) in hemophilia patients in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 1 | Status: COMPLETED